09/013871

```
* * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * *
*                                                                       *
*           Welcome to MESSENGER (APS Text) at USPTO                    *
*                                                                       *
*                                                                       *
*    The USPTO production files are current through:                    *
*    July 27,1999  for U.S. Patent Text Data.                          *
*    July 27,1999  for U.S. Current Classification Data.               *
*    July 27,1999  for U.S. Patent Image Data.                         *
*                                                                       *
* * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * *
* * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * *
*       * PLEASE USE 305-9000 FOR NEW TELEPHONE NUMBER *               *
*                                                                       *
* * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * *
* More U.S. patent data is now available on APS.  The new              *
* USOCR file contains patents issued in 1970, plus some               *
* patents that were missing from the USPAT file.  See the             *
* Patents News Folder under the Public Folders in e-mail for          *
* more information on using the new file.  Thank you.                 *
* * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * *
*  DISCLAIMER:                                                          *
*  Neither the United States Government, nor any agency               *
*  thereof, nor any of their contractors, subcontractors or           *
*  employees make any warranty, expressed or implied,                 *
*  including any warranty of marketability of fitness for a           *
*  particular purpose; nor assumes any legal liability or             *
*  responsibility for any party's use, or the results of              *
*  such, of the data.                                                 *
* * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * *
*                Help Desk --> 703-305-9000                           *
*                                                                       *
*    The Help Desk is staffed for APS support 7 days/week.            *
*      Monday through Friday:      6:30am - 9:00pm                    *
*      Saturday, Sunday, Holidays: 8:30am - 5:00 pm                   *
*                                                                       *
*    The Help Desk staff at this number will handle all APS           *
*    related questions.                                                 *
* * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * *
*    >>>>>>>>>>>>> NEW SUNDAY HOURS !!! <<<<<<<<<<<<<                  *
*                                                                       *
*    The APS is available:                                              *
*            6:30am - 9:00pm Monday through Friday                      *
*            7:30am - 5:00pm Saturday, Sunday, Holidays                 *
*                                                                       *
*      APS is unavailable Thanksgiving Day, Christmas Day,              *
*      and New Year's Day.                                              *
*                                                                       *
* * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * *
FILE 'USPAT' ENTERED AT 15:10:23 ON 29 JUL 1999

* * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * *
*        U. S.   P A T E N T   T E X T   F I L E                      *
*                                                                       *
*  THE WEEKLY PATENT TEXT AND IMAGE DATA IS CURRENT                   *
*  THROUGH July 27,1999                                               *
*                                                                       *
*                                                                       *
```

* *

```
=> s (dreg(w)200)(P)(humanis? or humaniz?)

          167 DREG
       586673 200
          114 HUMANIS?
         1381 HUMANIZ?
L1           0 (DREG(W)200)(P)(HUMANIS? OR HUMANIZ?)

=> s dreg(w)200 or dreg200

          167 DREG
       586673 200
            5 DREG(W)200
            0 DREG200
L2          5 DREG(W)200 OR DREG200

=> d l2 1-5
```

1. 5,880,091, Mar. 9, 1999, Glycoprotein ligand for P-selectin and methods of use thereof; Richard D. Cummings, et al., 514/8; 424/143.1; 436/503; 514/54; 530/395, 396; 536/55.1, 55.2, 123.1 [IMAGE AVAILABLE]

2. 5,852,175, Dec. 22, 1998, P-selectin glycoprotein ligand blocking antibodies; Richard D. Cummings, et al., 530/388.73, 387.1, 387.5, 388.1, 388.22, 388.7, 389.1, 389.6 [IMAGE AVAILABLE]

3. 5,756,095, May 26, 1998, Antibodies with specificity for a common epitope on E-selectin and L-selectin; Mark A. Jutila, 424/144.1, 143.1, 152.1, 153.1, 154.1, 172.1, 173.1; 435/7.1, 7.2, 7.21, 7.24, 70.21, 449, 452; 530/388.2, 388.22, 388.73, 388.75, 389.6 [IMAGE AVAILABLE]

4. 5,464,778, Nov. 7, 1995, Glycoprotein ligand for P-selectin and methods of use thereof; Richard D. Cummings, et al., 436/503; 435/7.1, 7.24; 436/501; 536/53, 55.1, 55.2, 123.1 [IMAGE AVAILABLE]

5. 5,316,913, May 31, 1994, Neutrophil LECAM-1 as indicator of neutrophil activation; Eugene C. Butcher, et al., 435/7.24, 7.94, 975; 436/518, 536, 548 [IMAGE AVAILABLE]

```
=> d l2 1-5 date
```

L2: 1 of 5

TITLE:	Glycoprotein ligand for P-selectin and methods of use thereof		
US PAT NO:	5,880,091 [IMAGE AVAILABLE]	DATE ISSUED:	Mar. 9, 1999
APPL-NO:	08/473,253	DATE FILED:	Jun. 7, 1995
REL-US-DATA:	Continuation of Ser. No. 278,551, Jul. 21, 1994, Pat. No. 5,464,778, which is a continuation of Ser. No. 976,552, Nov. 16, 1992, abandoned, which is a continuation-in-part of Ser. No. 650,484, Feb. 5, 1991, abandoned, which is a continuation-in-part of Ser. No. 554,199, Jul. 17, 1990, abandoned, which is a continuation-in-part of Ser. No. 320,408, Mar. 8, 1989, Pat. No. 5,378,464.		

L2: 2 of 5

TITLE:	P-selectin glycoprotein ligand blocking antibodies		
US PAT NO:	5,852,175 [IMAGE AVAILABLE]	DATE ISSUED:	Dec. 22, 1998
APPL-NO:	08/438,280	DATE FILED:	May 10, 1995
REL-US-DATA:	Division of Ser. No. 278,551, Jul. 21, 1994, Pat. No.		

5,464,778, which is a continuation of Ser. No. 976,552, Nov. 16, 1992, abandoned, which is a continuation-in-part of Ser. No. 650,484, Feb. 5, 1991, abandoned, which is a continuation-in-part of Ser. No. 554,199, Jul. 17, 1990, abandoned, which is a continuation-in-part of Ser. No. 320,408, Mar. 8, 1989, Pat. No. 5,378,464.

L2: 3 of 5

TITLE: Antibodies with specificity for a common epitope on E-selectin and L-selectin
US PAT NO: 5,756,095 DATE ISSUED: May 26, 1998
[IMAGE AVAILABLE]
APPL-NO: 08/463,707 DATE FILED: Jun. 5, 1995
REL-US-DATA: Continuation of Ser. No. 64,505, May 19, 1993, abandoned, which is a continuation-in-part of Ser. No. 887,695, May 22, 1992, abandoned.

L2: 4 of 5

TITLE: Glycoprotein ligand for P-selectin and methods of use thereof
US PAT NO: 5,464,778 DATE ISSUED: Nov. 7, 1995
[IMAGE AVAILABLE]
APPL-NO: 08/278,551 DATE FILED: Jul. 21, 1994
REL-US-DATA: Continuation of Ser. No. 976,552, Nov. 16, 1992, abandoned, which is a continuation-in-part of Ser. No. 650,484, Feb. 5, 1991, abandoned, which is a continuation-in-part of Ser. No. 554,199, Jul. 17, 1990, abandoned, which is a continuation-in-part of Ser. No. 320,408, Mar. 8, 1989, Pat. No. 5,378,464.

L2: 5 of 5

TITLE: Neutrophil LECAM-1 as indicator of neutrophil activation
US PAT NO: 5,316,913 DATE ISSUED: May 31, 1994
[IMAGE AVAILABLE]
APPL-NO: 07/755,749 DATE FILED: Sep. 6, 1991

=> d l2 1-5 kwic

US PAT NO: 5,880,091 [IMAGE AVAILABLE] L2: 1 of 5

DETDESC:

DETD(5)

The . . . mAb (Leu-22) was purchased from Becton Dickinson & Co. (San Jose, Calif.). The anti-L-selectin murine mAb antibodies DREG-56, DREG-55, and **DREG-200**, described by Kishimoto et al., "Identification of a human peripheral lymph node receptor: a rapidly down-regulated adhesion receptor" proc. Natl.. . .

DETDESC:

DETD(48)

Membrane . . . membranes, and probed with [.sup.125 I]P-selectin or murine monoclonal antibodies directed against human lamp-1 (CR3), human lamp-2 (BB6), human L-selectin (**DREG-200**), or human leukosialin (Leu22). Western blot analysis of neutrophil membranes with mabs to lamp-1 and lamp-2 showed that the electrophoretic. . .

DETDESC:

DETD(51)

Parallel . . . assessed by indirect immunofluorescence using a phycoerythrin-conjugated anti-murine IgG.sub.1 antibody. Identical results were obtained with the anti-L-selectin mAbs DREG-55 and **DREG-200**. Thus, interactions with L-selectin do not appear to contribute to the binding of fluid-phase P-selectin to intact neutrophils or to. . .

US PAT NO: 5,852,175 [IMAGE AVAILABLE] L2: 2 of 5

DETDESC:

DETD(10)

The . . . mAb (Leu-22) was purchased from Becton Dickinson & Co. (San Jose, Calif.). The anti-L-selectin murine mAb antibodies DREG-56, DREG-55, and **DREG-200**, described by Kishimoto et al., "Identification of a human peripheral lymph node receptor: a rapidly down-regulated adhesion receptor" proc. Natl.. . .

DETDESC:

DETD(52)

Membrane . . . membranes, and probed with [.sup.125 I]P-selectin or murine monoclonal antibodies directed against human lamp-1 (CR3), human lamp-2 (BB6), human L-selectin (**DREG-200**), or human leukosialin (Leu22). Western blot analysis of neutrophil membranes with mAbs to lamp-1 and lamp-2 showed that the electrophoretic. . .

DETDESC:

DETD(55)

Parallel . . . assessed by indirect immunofluorescence using a phycoerythrin-conjugated anti-murine IgG, antibody. Identical results were obtained with the anti-L-selectin mAbs DREG-55 and **DREG-200**. Thus, interactions with L-selectin do not appear to contribute to the binding of fluid-phase P-selectin to intact neutrophils or to. . .

US PAT NO: 5,756,095 [IMAGE AVAILABLE] L2: 3 of 5

DETDESC:

DETD(65)

Leu-8 (purchased from Becton Dickinson & Co., Mountainview, Calif.) and DREG series of mAb (DREG 56, **DREG 200**, and DREG 152), which are mouse IgGs that have been shown to recognize human L-selectin (Camerini et al., 1989 Nature. . .

DETDESC:

DETD(103)

Additional . . . these results are that EL-246 does not block the lectin activity of L-selectin or cross-block the binding of four mAbs (**DREG 200**, DREG 55, DREG 56, and Leu-8) that recognize the L-selectin domain.

US PAT NO: 5,464,778 [IMAGE AVAILABLE] L2: 4 of 5

DETDESC:

DETD(10)

The . . . mAb (Leu-22) was purchased from Becton Dickinson & Co. (San

Jose, Calif.). The anti-L-selectin murine mAb antibodies DREG-56, DREG-55, and **DREG-200**, described by Kishimoto et al., "Identification of a human peripheral lymph node receptor: a rapidly down-regulated adhesion receptor" proc. Natl.. . .

DETDESC:

DETD(52)

Membrane . . . membranes, and probed with [.sup.125 I]P-selectin or murine monoclonal antibodies directed against human lamp-1 (CR3), human lamp-2 (BB6), human L-selectin (**DREG-200**), or human leukosialin (Leu22). Western blot analysis of neutrophil membranes with mAbs to lamp-1 and lamp-2 showed that the electrophoretic. . .

DETDESC:

DETD(55)

Parallel . . . assessed by indirect immunofluorescence using a phycoerythrin-conjugated anti-murine IgG.sub.1 antibody. Identical results were obtained with the anti-L-selectin mAbs DREG-55 and **DREG-200**. Thus, interactions with L-selectin do not appear to contribute to the binding of fluid-phase P-selectin to intact neutrophils or to. . .

US PAT NO: 5,316,913 [IMAGE AVAILABLE] L2: 5 of 5

DETDESC:

DETD(20)

MAbs: The production and characterization of the Dreg-56 and **Dreg-200** mAbs against human LECAM-1 has been described previously (Kishimoto et al., (1990) PNAS USA 87:2244-2248). The CL2 and CL3 mAbs. . .

DETDESC:

DETD(25)

The . . . compared for maximum dilution giving detectable reactivity). After initial concentration adjustment, all preparations were re-analyzed by a precise ELISA using **Dreg-200**, HECA-452, CSLEX-1, and isotype-matched controls-as primary detection mAbs. ELISAs were performed on serial dilutions of the Ag (in triplicate) directly. . . LECAM-1 preparations were normalized such that equivalent dilutions gave a 1/2 maximal response in OD at 490 nm using the **Dreg-200** mAb.

DETDESC:

DETD(35)

The . . . mAbs against LECAM-1 epitopes common to both PMN and lymphocytes (i.e. mAbs not primarily recognizing specific oligosaccharide epitopes; Dreg-56 and **Dreg-200**) also resulted in nearly 60% inhibition of L1-2.sup.ELAM-1 binding. These results clearly demonstrate that PMN, but not lymphocyte, LECAM-1 is. . .

=> s dreg(w)55 or dreg55

```
          167 DREG
       481905 55
            4 DREG(W)55
            1 DREG55
```

L3 4 DREG(W)55 OR DREG55

=> d l3 1-4 date

L3: 1 of 4

TITLE: Glycoprotein ligand for P-selectin and methods of use thereof
US PAT NO: 5,880,091 DATE ISSUED: Mar. 9, 1999
[IMAGE AVAILABLE]
APPL-NO: 08/473,253 DATE FILED: Jun. 7, 1995
REL-US-DATA: Continuation of Ser. No. 278,551, Jul. 21, 1994, Pat. No. 5,464,778, which is a continuation of Ser. No. 976,552, Nov. 16, 1992, abandoned, which is a continuation-in-part of Ser. No. 650,484, Feb. 5, 1991, abandoned, which is a continuation-in-part of Ser. No. 554,199, Jul. 17, 1990, abandoned, which is a continuation-in-part of Ser. No. 320,408, Mar. 8, 1989, Pat. No. 5,378,464.

L3: 2 of 4

TITLE: P-selectin glycoprotein ligand blocking antibodies
US PAT NO: 5,852,175 DATE ISSUED: Dec. 22, 1998
[IMAGE AVAILABLE]
APPL-NO: 08/438,280 DATE FILED: May 10, 1995
REL-US-DATA: Division of Ser. No. 278,551, Jul. 21, 1994, Pat. No. 5,464,778, which is a continuation of Ser. No. 976,552, Nov. 16, 1992, abandoned, which is a continuation-in-part of Ser. No. 650,484, Feb. 5, 1991, abandoned, which is a continuation-in-part of Ser. No. 554,199, Jul. 17, 1990, abandoned, which is a continuation-in-part of Ser. No. 320,408, Mar. 8, 1989, Pat. No. 5,378,464.

L3: 3 of 4

TITLE: Antibodies with specificity for a common epitope on E-selectin and L-selectin
US PAT NO: 5,756,095 DATE ISSUED: May 26, 1998
[IMAGE AVAILABLE]
APPL-NO: 08/463,707 DATE FILED: Jun. 5, 1995
REL-US-DATA: Continuation of Ser. No. 64,505, May 19, 1993, abandoned, which is a continuation-in-part of Ser. No. 887,695, May 22, 1992, abandoned.

L3: 4 of 4

TITLE: Glycoprotein ligand for P-selectin and methods of use thereof
US PAT NO: 5,464,778 DATE ISSUED: Nov. 7, 1995
[IMAGE AVAILABLE]
APPL-NO: 08/278,551 DATE FILED: Jul. 21, 1994
REL-US-DATA: Continuation of Ser. No. 976,552, Nov. 16, 1992, abandoned, which is a continuation-in-part of Ser. No. 650,484, Feb. 5, 1991, abandoned, which is a continuation-in-part of Ser. No. 554,199, Jul. 17, 1990, abandoned, which is a continuation-in-part of Ser. No. 320,408, Mar. 8, 1989, Pat. No. 5,378,464.

=> d l3 1-4 kwic

US PAT NO: 5,880,091 [IMAGE AVAILABLE] L3: 1 of 4

DETDESC:

DETD(5)

The . . . leukosialin (CD43) mAb (Leu-22) was purchased from Becton Dickinson & Co. (San Jose, Calif.). The anti-L-selectin murine mAb antibodies DREG-56, **DREG-55**, and DREG-200, described by Kishimoto et al., "Identification of a human peripheral lymph node receptor: a rapidly down-regulated adhesion receptor". . .

DETDESC:

DETD(51)

Parallel . . . neutrophils was assessed by indirect immunofluorescence using a phycoerythrin-conjugated anti-murine IgG.sub.1 antibody. Identical results were obtained with the anti-L-selectin mAbs **DREG-55** and DREG-200. Thus, interactions with L-selectin do not appear to contribute to the binding of fluid-phase P-selectin to intact neutrophils. . .

US PAT NO: 5,852,175 [IMAGE AVAILABLE] L3: 2 of 4

DETDESC:

DETD(10)

The . . . leukosialin (CD43) mAb (Leu-22) was purchased from Becton Dickinson & Co. (San Jose, Calif.). The anti-L-selectin murine mAb antibodies DREG-56, **DREG-55**, and DREG-200, described by Kishimoto et al., "Identification of a human peripheral lymph node receptor: a rapidly down-regulated adhesion receptor". . .

DETDESC:

DETD(55)

Parallel . . . neutrophils was assessed by indirect immunofluorescence using a phycoerythrin-conjugated anti-murine IgG, antibody. Identical results were obtained with the anti-L-selectin mAbs **DREG-55** and DREG-200. Thus, interactions with L-selectin do not appear to contribute to the binding of fluid-phase P-selectin to intact neutrophils. . .

US PAT NO: 5,756,095 [IMAGE AVAILABLE] L3: 3 of 4

DRAWING DESC:

DRWD(16)

FIG. . . . lymphocytes that homed into blood spleen and peripheral lymph nodes (PLN) following treatment (trtd.) with EL-246 (FIGS. 13G through 13I), **DREG 55** (FIGS. 13D through 13F) or medium alone (FIGS. 13A through 13C) (control).

DETDESC:

DETD(65)

Leu-8 . . . second stage or as fluorescein isothiocyanate (FITC) conjugates. The DREG mAbs were partially purified by ammonium sulphate precipitation. Other mAbs, **DREG55** (mouse anti-L-selectin IgG1, SH43 (mouse IgG1 anti-sheep platelet, Jutila M. A. unpublished) and EL-81 (mouse IgG1 anti-ELAM-1), were used as. . .

DETDESC:

DETD(103)

Additional . . . are that EL-246 does not block the lectin activity

of L-selectin or cross-block the binding of four mAbs (DREG 200, **DREG 55**, DREG 56, and Leu-8) that recognize the L-selectin domain.

DETDESC:

DETD(194)

The effect of a negative control antibody (**DREG55**) was examined. This antibody is the same isotype and was prepared in the same manner as EL-246 but does not. . . vivo homing assay was done as described in Table 2, and the effects of EL-246 and a negative control antibody (**DREG55** same isotype as EL-246, but does not recognize bovine lymphocytes) were evaluated by flow cytometry. The contour plots shown in. . . this experiment and report the percentage of FITC-labeled bovine lymphocytes that homed into spleen and PLN following treatment with EL-246, **DREG 55**, or medium alone (control). 50,000 cells were analyzed for each time point and the threshold for the contour levels were. . .

DETDESC:

DETD(195)

FIG. 13 shows representative flow cytometric contour plots of the data collected from animals injected with medium alone, **DREG55**, and EL-246-treated, FITC-labeled cells. Again, EL-246 blocked homing to the peripheral lymph node and slightly diminished accumulation in the spleen. **DREG55** had no effect on the accumulation of cells in the PLN; however it affected accumulation in the spleen to the same extent as EL-246. Importantly, EL-246 blocked homing to PLN by 70% in comparison to the effect of **DREG55**, even though there were 2 times the level of circulating EL-246-treated versus **DREG55**-treated cells in the test animals. These results show that EL-246 is an effective inhibitor of L-selectin in this in vivo. . .

US PAT NO: 5,464,778 [IMAGE AVAILABLE] L3: 4 of 4

DETDESC:

DETD(10)

The . . . leukosialin (CD43) mAb (Leu-22) was purchased from Becton Dickinson & Co. (San Jose, Calif.). The anti-L-selectin murine mAb antibodies DREG-56, **DREG-55**, and DREG-200, described by Kishimoto et al., "Identification of a human peripheral lymph node receptor: a rapidly down-regulated adhesion receptor". . .

DETDESC:

DETD(55)

Parallel . . . neutrophils was assessed by indirect immunofluorescence using a phycoerythrin-conjugated anti-murine IgG.sub.1 antibody. Identical results were obtained with the anti-L-selectin mAbs **DREG-55** and DREG-200. Thus, interactions with L-selectin do not appear to contribute to the binding of fluid-phase P-selectin to intact neutrophils. . .

09/013871

```
* * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * *
*                                                                       *
*            Welcome to MESSENGER (APS Text) at USPTO                   *
*                                                                       *
*                                                                       *
*    The USPTO production files are current through:                    *
*    July 27,1999  for U.S. Patent Text Data.                          *
*    July 27,1999  for U.S. Current Classification Data.               *
*    July 27,1999  for U.S. Patent Image Data.                         *
*                                                                       *
* * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * *
* * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * *
*       * PLEASE USE 305-9000 FOR NEW TELEPHONE NUMBER *               *
*                                                                       *
* * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * *
* More U.S. patent data is now available on APS.  The new              *
* USOCR file contains patents issued in 1970, plus some               *
* patents that were missing from the USPAT file.  See the             *
* Patents News Folder under the Public Folders in e-mail for          *
* more information on using the new file.  Thank you.                 *
* * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * *
*  DISCLAIMER:                                                          *
*  Neither the United States Government, nor any agency               *
*  thereof, nor any of their contractors, subcontractors or           *
*  employees make any warranty, expressed or implied,                 *
*  including any warranty of marketability of fitness for a           *
*  particular purpose; nor assumes any legal liability or             *
*  responsibility for any party's use, or the results of              *
*  such, of the data.                                                 *
* * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * *
*                Help Desk --> 703-305-9000                           *
*                                                                       *
*    The Help Desk is staffed for APS support 7 days/week.            *
*      Monday through Friday:      6:30am - 9:00pm                    *
*      Saturday, Sunday, Holidays: 8:30am - 5:00 pm                   *
*                                                                       *
*    The Help Desk staff at this number will handle all APS           *
*    related questions.                                                 *
* * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * *
*    >>>>>>>>>>>>> NEW SUNDAY HOURS !!! <<<<<<<<<<<<<                  *
*                                                                       *
*    The APS is available:                                              *
*            6:30am - 9:00pm Monday through Friday                      *
*            7:30am - 5:00pm Saturday, Sunday, Holidays                 *
*                                                                       *
*      APS is unavailable Thanksgiving Day, Christmas Day,              *
*      and New Year's Day.                                              *
*                                                                       *
* * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * *
FILE 'USPAT' ENTERED AT 14:00:59 ON 29 JUL 1999

* * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * *
*        U. S.   P A T E N T   T E X T   F I L E                       *
*                                                                       *
*  THE WEEKLY PATENT TEXT AND IMAGE DATA IS CURRENT                     *
*  THROUGH July 27,1999                                               *
*                                                                       *
```

```
  *                                                                    *
  * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * *

=> s (heart(w)lung or acute(w)organ or extracoporeal or polytraumatic or
organ(w)failure)

         50305 HEART
         19559 LUNG
          1714 HEART(W)LUNG
         86012 ACUTE
         24104 ORGAN
            21 ACUTE(W)ORGAN
            41 EXTRACOPOREAL
            18 POLYTRAUMATIC
         24104 ORGAN
        190458 FAILURE
           406 ORGAN(W)FAILURE
L1        2185 (HEART(W)LUNG OR ACUTE(W)ORGAN OR EXTRACOPOREAL OR POLYTRAU
MAT
               IC OR ORGAN(W)FAILURE)

=> s l1(P)(selectin? or l(w)selectin or lam1 or lam(w)1 or leccam)

        224452 SELECTIN?
        577264 L
           451 SELECTIN
            12 LAM1
          1643 LAM
       2477259 1
            17 LECCAM
L2          10 L1(P)(SELECTIN? OR L(W)SELECTIN OR LAM1 OR LAM(W)1 OR LECCA
M)

=> d l2 1-10 date


                                                          L2: 1 of 10
TITLE:          Di- and trivalent small molecule selectin inhibitors
US PAT NO:      5,919,768                 DATE ISSUED:    Jul. 6, 1999
                [IMAGE AVAILABLE]
APPL-NO:        08/981,580                DATE FILED:     Feb. 11, 1998
PCT-NO:         PCT/US96/11032            PCT-FILED:      Jun. 26, 1996
                                          371-DATE:       Feb. 11, 1998
                                          102(E)-DATE:    Feb. 11, 1998
PCT-PUB-NO:     WO97/01335                PCT-PUB-DATE:   Jan. 16, 1997

                                                          L2: 2 of 10
TITLE:          Tumor necrosis factor antagonists and their use
US PAT NO:      5,795,967                 DATE ISSUED:    Aug. 18, 1998
                [IMAGE AVAILABLE]
APPL-NO:        08/482,226                DATE FILED:     Jun. 7, 1995
REL-US-DATA:    Continuation of Ser. No. 342,676, Nov. 21, 1994,
                  abandoned, which is a continuation of Ser. No. 174,212,
                  Dec. 28, 1993, abandoned, which is a continuation of
                  Ser. No. 26,717, Mar. 5, 1993, abandoned, which is a
                  continuation of Ser. No. 707,412, May 28, 1991,
                  abandoned, which is a continuation of Ser. No. 417,171,
                  Oct. 4, 1989, abandoned, which is a continuation of Ser.
                  No. 898,272, Aug. 20, 1986, abandoned, which is a
                  continuation-in-part of Ser. No. 754,507, Jul. 12, 1985,
                  abandoned, and Ser. No. 881,311, Jul. 2, 1986,
                  abandoned, which is a continuation-in-part of Ser. No.
                  677,156, Dec. 3, 1984, abandoned, which is a
                  continuation-in-part of Ser. No. 627,959, Jul. 5, 1984,
                  abandoned.
```

L2: 3 of 10

TITLE: Anti-LAM 1-3 antibody and hybridoma
US PAT NO: 5,776,775 DATE ISSUED: Jul. 7, 1998
[IMAGE AVAILABLE]
APPL-NO: 08/215,366 DATE FILED: Mar. 21, 1994
REL-US-DATA: Continuation of Ser. No. 720,602, Jun. 25, 1991, abandoned, which is a continuation-in-part of Ser. No. 313,109, Feb. 21, 1989, abandoned.

L2: 4 of 10

TITLE: Method for identifying and isolating cells expressing leukocyte adhesion molecule-1
US PAT NO: 5,776,707 DATE ISSUED: Jul. 7, 1998
[IMAGE AVAILABLE]
APPL-NO: 08/478,949 DATE FILED: Jun. 7, 1995
REL-US-DATA: Continuation of Ser. No. 215,366, Mar. 21, 1994, which is a continuation of Ser. No. 720,602, Jun. 25, 1991, abandoned, which is a continuation-in-part of Ser. No. 313,109, Feb. 21, 1989, abandoned.

L2: 5 of 10

TITLE: Methods of blocking adhesion with anti-lami-3 antibody
US PAT NO: 5,679,346 DATE ISSUED: Oct. 21, 1997
[IMAGE AVAILABLE]
APPL-NO: 08/481,803 DATE FILED: Jun. 7, 1995
REL-US-DATA: Division of Ser. No. 215,366, Mar. 21, 1994, which is a continuation of Ser. No. 720,602, Jun. 25, 1991, abandoned, which is a continuation-in-part of Ser. No. 313,109, Feb. 21, 1989, abandoned.

L2: 6 of 10

TITLE: Tumor necrosis factor antagonists and their use
US PAT NO: 5,672,347 DATE ISSUED: Sep. 30, 1997
[IMAGE AVAILABLE]
APPL-NO: 08/435,934 DATE FILED: May 5, 1995
REL-US-DATA: Division of Ser. No. 342,676, Nov. 21, 1994, abandoned, which is a continuation of Ser. No. 174,212, Dec. 28, 1993, abandoned, which is a continuation of Ser. No. 26,717, Mar. 5, 1993, abandoned, which is a continuation of Ser. No. 707,412, May 28, 1991, abandoned, which is a continuation of Ser. No. 417,171, Oct. 4, 1989, abandoned, which is a continuation of Ser. No. 898,272, Aug. 20, 1986, abandoned, which is a continuation-in-part of Ser. No. 754,507, Jul. 12, 1985, abandoned, and Ser. No. 881,311, Jul. 2, 1986, abandoned, which is a continuation-in-part of Ser. No. 677,156, Dec. 3, 1984, abandoned, which is a continuation-in-part of Ser. No. 627,959, Jul. 5, 1984, abandoned.

L2: 7 of 10

TITLE: Noninvasive diagnosis for allograft rejection
US PAT NO: 5,635,365 DATE ISSUED: Jun. 3, 1997
[IMAGE AVAILABLE]
APPL-NO: 08/512,184 DATE FILED: Aug. 7, 1995

L2: 8 of 10

TITLE: Compositions and methods of inhibiting the binding of E-selectin or P-selectin or sialyl-Lewis.sup.x or sialyl-Lewis.sup.a
US PAT NO: 5,622,937 DATE ISSUED: Apr. 22, 1997
[IMAGE AVAILABLE]
APPL-NO: 08/641,341 DATE FILED: May 1, 1996
REL-US-DATA: Continuation of Ser. No. 236,517, Apr. 29, 1994, abandoned.

L2: 9 of 10

TITLE: Binding of E-selectin or P-selectin to sialyl Lewis.sup.x or sialyl-Lewis.sup.a
US PAT NO: 5,444,050 [IMAGE AVAILABLE] DATE ISSUED: Aug. 22, 1995
APPL-NO: 08/235,293 DATE FILED: Apr. 29, 1994

L2: 10 of 10

TITLE: Method of testing a donor liver for transplant
US PAT NO: 5,260,188 [IMAGE AVAILABLE] DATE ISSUED: Nov. 9, 1993
APPL-NO: 07/885,184 DATE FILED: May 19, 1992

=> d l2 1-10 kwic

US PAT NO: 5,919,768 [IMAGE AVAILABLE] L2: 1 of 10

SUMMARY:

BSUM(8)

While . . . therapeutic agents. Thus, it would be usefill to develop inhibitors that would prevent the binding of white blood cells to E-**selectin** or P-**selectin**. For example, some of the diseases that might be treated by the inhibition of **selectin** binding to sLe.sup.x include, but are not limited to, ARDS, Crohn's disease, septic shock, traumatic shock, multi-**organ failure**, autoimmune diseases, asthma, inflammatory bowel disease, psoriasis, rheumatoid arthritis and reperfusion injury that occurs following heart attacks, strokes and organ. . .

SUMMARY:

BSUM(58)

In . . . as psoriasis and rheumatoid arthritis, and reperfusion tissue injury that occurs following heat attacks, strokes and organ transplants, traumatic shock, multi-**organ failure**, autoimmune diseases, asthma and inflammatory bowel disease. In each case, an effective amount of the compounds of the present invention. . . be administered to treat other diseases that are associated with cell-cell adhesion. As the present compounds inhibit the binding of E-**selectin** or P-**selectin** with sLe.sup.X or sLe.sup.a, any disease that is related to this interaction may potentially be treated by the inhibition of. . .

US PAT NO: 5,795,967 [IMAGE AVAILABLE] L2: 2 of 10

SUMMARY:

BSUM(37)

The . . . or arthritis (injections into synovial fluid). Similar dosages and considerations apply in the case of TNF-.beta.. The key factor in **selecting** an appropriate dose is the result obtained: If the patient's inflammatory response does not at least partially resolve within about. . . relatively higher doses will be initially needed for the treatment for acute rejection or inflammatory episodes, i.e., for patients in **acute organ** transplant rejection or undergoing arthritic flares.

US PAT NO: 5,776,775 [IMAGE AVAILABLE] L2: 3 of 10

SUMMARY:

BSUM(14)

Neutrophil-mediated inflammation is involved in a number of human clinical manifestations, including the adult respiratory distress syndrome, multi-**organ failure** and reperfusion injury. One way of inhibiting this type of inflammatory response would be to block competitively the adhesive interactions between neutrophils and the endothelium adjacent to the inflamed region. Anti-LAM1-3 reacts with **LAM-1** on many animal species, but does not bind the mLHR. Anti-LAM1-3 blocks completely lymphocytic traffic to lymph nodes and extravasation. . .

US PAT NO: 5,776,707 [IMAGE AVAILABLE] L2: 4 of 10

SUMMARY:

BSUM(13)

Neutrophil-mediated inflammation is involved in a number of human clinical manifestations, including the adult respiratory distress syndrome, multi-**organ failure** and reperfusion injury. One way of inhibiting this type of inflammatory response would be to block competitively the adhesive interactions between neutrophils and the endothelium adjacent to the inflamed region. Anti-LAM1-3 reacts with **LAM-1** on many animal species, but does not bind the mLHR. Anti-LAM1-3 blocks completely lymphocytic traffic to lymph nodes and extravasation. . .

US PAT NO: 5,679,346 [IMAGE AVAILABLE] L2: 5 of 10

DETDESC:

DETD(22)

Neutrophil-mediated inflammation is involved in a number of human clinical manifestations, including the adult respiratory distress syndrome, multi-**organ failure** and reperfusion injury. One way of inhibiting this type of inflammatory response would be to block competitively the adhesive interactions between neutrophils and the endothelium adjacent to the inflamed region. Anti-LAM1-3 reacts with **LAM-1** on many animal species, but does not bind the mLHR. Anti-LAM1-3 blocks completely lymphocytic traffic to lymph nodes and extravasation. . .

US PAT NO: 5,672,347 [IMAGE AVAILABLE] L2: 6 of 10

SUMMARY:

BSUM(37)

The . . . or arthritis (injections into synovial fluid). Similar dosages and considerations apply in the case of TNF-.beta.. The key factor in **selecting** an appropriate dose is the result obtained: If the patient's inflammatory response does not at least partially resolve within about. . . relatively higher doses will be initially needed for the treatment for acute rejection or inflammatory episodes, i.e., for patients in **acute organ** transplant rejection or undergoing arthritic flares.

US PAT NO: 5,635,365 [IMAGE AVAILABLE] L2: 7 of 10

SUMMARY:

BSUM(9)

The present invention provides a non-invasive method for the diagnosis

and/or prediction of allograft rejection, for example, in human **heart**, **lung**, liver, kidney, bone marrow, pancreas or other solid organ transplant recipients. This method includes the step of obtaining a sample. . . . the transplant recipient exceeds the frequency in the normal population. One method of determining the frequency of Hprt-negative cells is **selecting** for the growth of those cells in the presence of 6-thioguanine and determining the FMC/10.sup.6 (i.e., the frequency of Hprt-deficient. . .

US PAT NO: 5,622,937 [IMAGE AVAILABLE] L2: 8 of 10

SUMMARY:

BSUM(7)

While . . . Thus, it would be useful to develop inhibitors that would prevent the binding of white blood cells to E- or P-**selectin**. For example, some of the diseases that might be treated by the inhibition of **selectin** binding to sLe.sup.x include, but are not limited to, ARDS, Crohn's disease, septic shock, traumatic shock, multi-**organ failure**, autoimmune diseases, asthma, inflammatory bowel disease, psoriasis, rheumatoid arthritis and reperfusion injury that occurs following heart attacks, strokes and organ. . .

DETDESC:

DETD(34)

In . . . as psoriasis and rheumatoid arthritis, and reperfusion tissue injury that occurs following heat attacks, strokes and organ transplants, traumatic shock, multi-**organ failure**, autoimmune diseases, asthma and inflammatory bowel disease. In each case, an effective amount of the compounds of the present invention. . . to treat other diseases that are associated with cell-cell adhesion. As the present compounds inhibit the binding of E- or P-**selectin** with sLe.sup.x or sLe.sup.a, any disease that is related to this interaction may potentially be treated by the inhibition of. . .

US PAT NO: 5,444,050 [IMAGE AVAILABLE] L2: 9 of 10

SUMMARY:

BSUM(8)

While . . . therapeutic agents. Thus, it would be useful to develop inhibitors that would prevent the binding of white blood cells to E-**selectin** or P-**selectin**. For example, some of the diseases that might be treated by the inhibition of **selectin** binding to sLe.sup.x include, but are not limited to, ARDS, Crohn's disease, septic shock, traumatic shock, multi-**organ failure**, autoimmune diseases, asthma, inflammatory bowel disease, psoriasis, rheumatoid arthritis and reperfusion injury that occurs following heart attacks, strokes and organ. . .

SUMMARY:

BSUM(78)

In . . . as psoriasis and rheumatoid arthritis, and reperfusion tissue injury that occurs following heat attacks, strokes and organ transplants, traumatic shock, multi-**organ failure**, autoimmune diseases, asthma and inflammatory bowel disease. In each case, an effective amount of the compounds of the present invention. . . be administered to treat other diseases that are associated with cell-cell adhesion. As the present compounds inhibit the binding of E-**selectin** or P-**selectin** with sLe.sup.x or sLe.sup.a, any disease that is

related to this interaction may potentially be treated by the inhibition of. . .

US PAT NO: 5,260,188 [IMAGE AVAILABLE] L2: 10 of 10

SUMMARY:

BSUM(17)

It is, therefore, an object of the invention to provide a method for noninvasively **selecting** for transplant an organ for a patient which resists **organ failure** due to primary nonfunction, and, therefore, which eliminates the need for a retransplant operation.

=> d his

```
     (FILE 'USPAT' ENTERED AT 14:00:59 ON 29 JUL 1999)
L1          2185 S (HEART(W)LUNG OR ACUTE(W)ORGAN OR EXTRACOPOREAL OR POLYT
RAU
L2            10 S L1(P)(SELECTIN? OR L(W)SELECTIN OR LAM1 OR LAM(W)1 OR LE
CCA

=> s l1 and (L(W)selectin or lam1 or lam(w)1 or leccam?)

        577264 L
           451 SELECTIN
           181 L(W)SELECTIN
            12 LAM1
          1643 LAM
       2477259 1
           124 LAM(W)1
            18 LECCAM?
L3          22 L1 AND (L(W)SELECTIN OR LAM1 OR LAM(W)1 OR LECCAM?)

=>

=> d l3 1-22 date
```

L3: 1 of 22

TITLE: Ligand or GMP-140 selectin and methods of use thereof
US PAT NO: 5,929,036 [IMAGE AVAILABLE] DATE ISSUED: Jul. 27, 1999
APPL-NO: 08/469,543 DATE FILED: Jun. 6, 1995
REL-US-DATA: Division of Ser. No. 278,554, Jul. 21, 1994, which is a continuation of Ser. No. 650,484, Feb. 5, 1991, abandoned, which is a continuation-in-part of Ser. No. 554,199, Jul. 17, 1990, abandoned, which is a continuation-in-part of Ser. No. 320,408, Mar. 8, 1989, Pat. No. 5,378,464.

L3: 2 of 22

TITLE: Di- and trivalent small molecule selectin inhibitors
US PAT NO: 5,919,768 [IMAGE AVAILABLE] DATE ISSUED: Jul. 6, 1999
APPL-NO: 08/981,580 DATE FILED: Feb. 11, 1998
PCT-NO: PCT/US96/11032 PCT-FILED: Jun. 26, 1996
371-DATE: Feb. 11, 1998
102(E)-DATE: Feb. 11, 1998
PCT-PUB-NO: WO97/01335 PCT-PUB-DATE: Jan. 16, 1997

L3: 3 of 22

TITLE: Tissue factor compositions and ligands for the specific coagulation of vasculature
US PAT NO: 5,877,289 DATE ISSUED: Mar. 2, 1999

[IMAGE AVAILABLE]
APPL-NO: 08/479,733 DATE FILED: Jun. 7, 1995
REL-US-DATA: Continuation-in-part of Ser. No. 273,567, Jul. 11, 1994, which is a continuation-in-part of Ser. No. 205,330, Mar. 2, 1994, Pat. No. 5,855,866, which is a continuation-in-part of Ser. No. 846,349, Mar. 5, 1992.

L3: 4 of 22

TITLE: HTK ligand
US PAT NO: 5,864,020 DATE ISSUED: Jan. 26, 1999
[IMAGE AVAILABLE]
APPL-NO: 08/436,054 DATE FILED: May 5, 1995
REL-US-DATA: Division of Ser. No. 277,722, Jul. 20, 1994.

L3: 5 of 22

TITLE: Compositions comprising complement related proteins and carbohydrates, and methods for producing and using said compositions
US PAT NO: 5,856,300 DATE ISSUED: Jan. 5, 1999
[IMAGE AVAILABLE]
APPL-NO: 08/553,339 DATE FILED: Nov. 13, 1995
PCT-NO: PCT/US94/05285 PCT-FILED: May 12, 1994
371-DATE: Nov. 11, 1995
102(E)-DATE: Nov. 11, 1995
PCT-PUB-NO: WO94/26786 PCT-PUB-DATE: Nov. 24, 1994

L3: 6 of 22

TITLE: Use of chimeric selectins as simultaneous blocking agents for component selectin function
US PAT NO: 5,834,425 DATE ISSUED: Nov. 10, 1998
[IMAGE AVAILABLE]
APPL-NO: 08/461,592 DATE FILED: Jun. 5, 1995
REL-US-DATA: Division of Ser. No. 340,539, Nov. 16, 1994, which is a continuation of Ser. No. 8,459, Jan. 25, 1993, abandoned, which is a continuation-in-part of Ser. No. 983,606, Nov. 30, 1992, which is a continuation of Ser. No. 730,503, Jul. 8, 1991, abandoned, and Ser. No. 313,109, Feb. 21, 1989, abandoned, and a continuation-in-part of Ser. No. 700,773, May 15, 1991, abandoned, Ser. No. 737,092, Jul. 29, 1991, abandoned, Ser. No. 770,608, Oct. 3, 1991, abandoned, and Ser. No. 862,483, Apr. 2, 1992, Pat. No. 5,389,520.

L3: 7 of 22

TITLE: Chimeric selectins as simultaneous blocking agents for component selectin function
US PAT NO: 5,808,025 DATE ISSUED: Sep. 15, 1998
[IMAGE AVAILABLE]
APPL-NO: 08/340,539 DATE FILED: Nov. 16, 1994
REL-US-DATA: Continuation of Ser. No. 8,459, Jan. 25, 1993, abandoned.

L3: 8 of 22

TITLE: Method of inhibiting PADGEM-mediated or ELAM-1-mediated leukocyte adhesion using an inhibitor comprising a Le.sup.x core component
US PAT NO: 5,807,745 DATE ISSUED: Sep. 15, 1998
[IMAGE AVAILABLE]
APPL-NO: 08/379,080 DATE FILED: Jan. 26, 1995
REL-US-DATA: Continuation of Ser. No. 230,862, Apr. 19, 1994, abandoned, which is a continuation of Ser. No. 667,030, Mar. 11, 1991, abandoned.

L3: 9 of 22

TITLE: Anti-LAM 1-3 antibody and hybridoma
US PAT NO: 5,776,775 DATE ISSUED: Jul. 7, 1998
[IMAGE AVAILABLE]

APPL-NO: 08/215,366 DATE FILED: Mar. 21, 1994
REL-US-DATA: Continuation of Ser. No. 720,602, Jun. 25, 1991, abandoned, which is a continuation-in-part of Ser. No. 313,109, Feb. 21, 1989, abandoned.

L3: 10 of 22

TITLE: Method for identifying and isolating cells expressing leukocyte adhesion molecule-1
US PAT NO: 5,776,707 DATE ISSUED: Jul. 7, 1998
[IMAGE AVAILABLE]
APPL-NO: 08/478,949 DATE FILED: Jun. 7, 1995
REL-US-DATA: Continuation of Ser. No. 215,366, Mar. 21, 1994, which is a continuation of Ser. No. 720,602, Jun. 25, 1991, abandoned, which is a continuation-in-part of Ser. No. 313,109, Feb. 21, 1989, abandoned.

L3: 11 of 22

TITLE: Antibodies with specificity for a common epitope on E-selectin and **L-selectin**
US PAT NO: 5,756,095 DATE ISSUED: May 26, 1998
[IMAGE AVAILABLE]
APPL-NO: 08/463,707 DATE FILED: Jun. 5, 1995
REL-US-DATA: Continuation of Ser. No. 64,505, May 19, 1993, abandoned, which is a continuation-in-part of Ser. No. 887,695, May 22, 1992, abandoned.

L3: 12 of 22

TITLE: Adenoviral-mediated cell targeting commanded by the adenovirus penton base protein
US PAT NO: 5,712,136 DATE ISSUED: Jan. 27, 1998
[IMAGE AVAILABLE]
APPL-NO: 08/634,060 DATE FILED: Apr. 17, 1996
REL-US-DATA: Continuation-in-part of Ser. No. 303,162, Sep. 8, 1994, Pat. No. 5,559,099.

L3: 13 of 22

TITLE: Modified anti-ICAM-1 antibodies and their use in the treatment of inflammation
US PAT NO: 5,695,760 DATE ISSUED: Dec. 9, 1997
[IMAGE AVAILABLE]
APPL-NO: 08/427,355 DATE FILED: Apr. 24, 1995

L3: 14 of 22

TITLE: Methods of blocking adhesion with anti-lami-3 antibody
US PAT NO: 5,679,346 DATE ISSUED: Oct. 21, 1997
[IMAGE AVAILABLE]
APPL-NO: 08/481,803 DATE FILED: Jun. 7, 1995
REL-US-DATA: Division of Ser. No. 215,366, Mar. 21, 1994, which is a continuation of Ser. No. 720,602, Jun. 25, 1991, abandoned, which is a continuation-in-part of Ser. No. 313,109, Feb. 21, 1989, abandoned.

L3: 15 of 22

TITLE: Method for using Htk ligand
US PAT NO: 5,624,899 DATE ISSUED: Apr. 29, 1997
[IMAGE AVAILABLE]
APPL-NO: 08/436,044 DATE FILED: May 5, 1995
REL-US-DATA: Division of Ser. No. 277,722, Jul. 20, 1994.

L3: 16 of 22

TITLE: Compositions and methods of inhibiting the binding of E-selectin or P-selectin or sialyl-Lewis.sup.x or sialyl-Lewis.sup.a
US PAT NO: 5,622,937 DATE ISSUED: Apr. 22, 1997
[IMAGE AVAILABLE]
APPL-NO: 08/641,341 DATE FILED: May 1, 1996

REL-US-DATA: Continuation of Ser. No. 236,517, Apr. 29, 1994, abandoned.

L3: 17 of 22

TITLE: Cross-reacting monoclonal antibodies specific for E- and P-selectin

US PAT NO: 5,622,701 DATE ISSUED: Apr. 22, 1997
[IMAGE AVAILABLE]

APPL-NO: 08/259,963 DATE FILED: Jun. 14, 1994

L3: 18 of 22

TITLE: Methods for using monoclonal antibodies specific for cell-surface bound **LAM-1**

US PAT NO: 5,595,737 DATE ISSUED: Jan. 21, 1997
[IMAGE AVAILABLE]

APPL-NO: 08/477,394 DATE FILED: Jun. 7, 1995

REL-US-DATA: Division of Ser. No. 334,191, Nov. 4, 1994, which is a division of Ser. No. 862,483, Apr. 2, 1992, Pat. No. 5,389,520, Feb. 14, 1995, which is a continuation-in-part of Ser. No. 730,503, Jul. 8, 1991, abandoned, which is a continuation of Ser. No. 313,109, Feb. 21, 1989, abandoned, and a continuation-in-part of Ser. No. 700,773, May 15, 1991, abandoned, Ser. No. 737,092, Jul. 29, 1991, abandoned, and Ser. No. 770,608, Oct. 3, 1991, abandoned.

L3: 19 of 22

TITLE: Antisense oligonucleotides directed against human ELAM-I RNA

US PAT NO: 5,585,479 DATE ISSUED: Dec. 17, 1996
[IMAGE AVAILABLE]

APPL-NO: 08/136,741 DATE FILED: Oct. 12, 1993

REL-US-DATA: Continuation-in-part of Ser. No. 918,260, Jul. 24, 1992, abandoned.

L3: 20 of 22

TITLE: Binding of E-selectin or P-selectin to sialyl Lewis.sup.x or sialyl-Lewis.sup.a

US PAT NO: 5,444,050 DATE ISSUED: Aug. 22, 1995
[IMAGE AVAILABLE]

APPL-NO: 08/235,293 DATE FILED: Apr. 29, 1994

L3: 21 of 22

TITLE: Specific detection of cell surface receptor leukocyte adhesion molecule-1

US PAT NO: 5,389,520 DATE ISSUED: Feb. 14, 1995
[IMAGE AVAILABLE]

APPL-NO: 07/862,483 DATE FILED: Apr. 2, 1992

REL-US-DATA: Continuation-in-part of Ser. No. 730,503, Jul. 8, 1991, abandoned, which is a continuation of Ser. No. 313,109, Feb. 21, 1989, abandoned, and a continuation-in-part of Ser. No. 700,773, May 15, 1991, abandoned, and a continuation-in-part of Ser. No. 737,092, Jul. 29, 1991, abandoned, and a continuation-in-part of Ser. No. 770,608, Oct. 3, 1991.

L3: 22 of 22

TITLE: Functionally active selectin-derived peptides

US PAT NO: 5,198,424 DATE ISSUED: Mar. 30, 1993
[IMAGE AVAILABLE]

APPL-NO: 07/867,271 DATE FILED: Apr. 7, 1992

REL-US-DATA: Continuation of Ser. No. 554,199, Jul. 17, 1990, abandoned, which is a continuation-in-part of Ser. No. 320,408, Mar. 8, 1989.

L8: 6 of 11

TITLE: Biocompatible coated article
US PAT NO: 5,643,681 DATE ISSUED: Jul. 1, 1997
[IMAGE AVAILABLE]
APPL-NO: 08/473,723 DATE FILED: Jun. 7, 1995
REL-US-DATA: Continuation of Ser. No. 227,955, Apr. 15, 1994, abandoned.

L8: 7 of 11

TITLE: Two-step pretargeting methods using improved biotin-active agent conjugates
US PAT NO: 5,630,996 DATE ISSUED: May 20, 1997
[IMAGE AVAILABLE]
APPL-NO: 08/122,979 DATE FILED: Sep. 16, 1993
REL-US-DATA: Continuation-in-part of Ser. No. 995,381, Dec. 23, 1992, abandoned, and Ser. No. 995,383, Dec. 23, 1992, abandoned, each Ser. No. is a continuation-in-part of Ser. No. 895,588, Jun. 9, 1992, Pat. No. 5,283,342.

L8: 8 of 11

TITLE: Clearing agents useful in pretargeting methods
US PAT NO: 5,624,896 DATE ISSUED: Apr. 29, 1997
[IMAGE AVAILABLE]
APPL-NO: 08/462,765 DATE FILED: Jun. 5, 1995
REL-US-DATA: Continuation of Ser. No. 163,184, Dec. 7, 1993, abandoned, which is a continuation-in-part of Ser. No. 995,381, Dec. 23, 1992, abandoned, which is a continuation-in-part of Ser. No. 895,588, Jun. 9, 1992, Pat. No. 5,283,342.

L8: 9 of 11

TITLE: Hexose derivatized human serum albumin clearing agents
US PAT NO: 5,616,690 DATE ISSUED: Apr. 1, 1997
[IMAGE AVAILABLE]
APPL-NO: 08/133,613 DATE FILED: Oct. 8, 1993
REL-US-DATA: Continuation-in-part of Ser. No. 995,383, Dec. 23, 1992, abandoned, which is a continuation-in-part of Ser. No. 895,588, Jun. 9, 1992, Pat. No. 5,283,342.

L8: 10 of 11

TITLE: Biotinidase-resistant biotin-DOTA conjugates
US PAT NO: 5,608,060 DATE ISSUED: Mar. 4, 1997
[IMAGE AVAILABLE]
APPL-NO: 08/351,469 DATE FILED: Feb. 21, 1995
PCT-NO: PCT/US93/05406 PCT-FILED: Jun. 7, 1993
371-DATE: Feb. 21, 1995
102(E)-DATE: Feb. 21, 1995
PCT-PUB-NO: WO93/25240 PCT-PUB-DATE: Dec. 23, 1993
REL-US-DATA: Continuation-in-part of Ser. No. 995,383, Dec. 23, 1992, abandoned, and a continuation-in-part of Ser. No. 995,381, Dec. 23, 1992, abandoned, each Ser. No. is a continuation-in-part of Ser. No. 895,588, Jun. 9, 1992, Pat. No. 5,283,342, Feb. 1, 1994.

L8: 11 of 11

TITLE: Pretargeting methods and compounds
US PAT NO: 5,541,287 DATE ISSUED: Jul. 30, 1996
[IMAGE AVAILABLE]
APPL-NO: 08/345,811 DATE FILED: Nov. 22, 1994

REL-US-DATA: Continuation-in-part of Ser. No. 156,565, Nov. 22, 1993, abandoned, which is a continuation-in-part of Ser. No. 995,381, Dec. 23, 1992, abandoned, which is a continuation-in-part of Ser. No. 895,588, Jun. 9, 1992, Pat. No. 5,283,342, Feb. 1, 1994.

=> d l8 6 kwic

US PAT NO: 5,643,681 [IMAGE AVAILABLE] L8: 6 of 11

SUMMARY:

BSUM(2)

The . . . cells, where adverse physiological reactions such as clot initiation must be minimized or eliminated. Such biocompatible materials are useful in **extracorporeal** blood oxygenation devices, hemodialysis devices, and the like.

SUMMARY:

BSUM(7)

Although . . . component with a large blood contact area is a heat exchanger, commonly fabricated of metal, used to maintain a desired **extracorporeal** blood temperature. Aluminum, titanium and stainless steel are all used for various sorts of blood-contacting devices. Aluminum is reactive with. . .

SUMMARY:

BSUM(10)

The . . . is maximized and the need for biocompatibility is at a premium. The invention is also useful for metallic surfaces in **extracorporeal** blood processing devices, for example, thermistor probes, and heat exchangers. Biocompatibility is measured herein by the reduced tendency to induce. . .

DETDESC:

DETD(6)

A major deficiency of the base polymer compositions of porous membranes and the metal surfaces of **extracorporeal** blood processing devices lies in the fact that, to varying degrees, the materials are not biocompatible. Surprisingly, it has been. . .

DETDESC:

DETD(34)

Inertness . . . in blood reflects the formation of thrombin, TAT concentration has been suggested as a sensitive parameter of coagulation activity during **extracorporeal** circulation [Deguchi, K. et al. (1991) Am. J. Hematology 38:86-89]. Celgard membranes dip-coated with 0.5% SMA-423 (optimal surface concentration by. . .

DETDESC:

DETD(41)

Platelet . . . 4:221-229. SMA-treated polypropylene tubing was compared to uncoated tubing and uncoated polyvinyl chloride tubing. Animals were systemically heparinized to mimic **extracorporeal**

circulation conditions. Shunts were removed at 30 minute and three hour intervals. Samples of control and coated tubing were fixed. . .

DETDESC:

DETD(50)

Platelet . . . platelet GPIIb antigen associated with leukocytes in a fluorescence-activated cell sorter. Leukocyte activation was assessed by measuring any loss of **L-selectin** and CD11b expression. The data are shown in Table 2. See Gemmell, C. H. et al. (1995) J. Lab. Clin.. . .

DETDESC:

DETD(53)

TABLE 2

Platelet and Leukocyte Compatibility in vitro study

PLATELETS	NEUTROPHILS and MONOCYTES	LEUKOCYTES **L-selectin** Expression
Platelet Count %	% P-selectin CD11b Expression	
% Resting WB Microparticles Positive. . .		

DETDESC:

DETD(63)

Analysis of leukocyte activation revealed minimal upregulation of CD11b or **L-selectin** with any of the tested surfaces. The presence of SMA had no deleterious effect, however.